Effects of cogrinding with β-cyclodextrin on the solid state fentanyl

Journal of Pharmaceutical Sciences

Volumn 99, Issue 12, 2010, Pages 5019-5029

  Ogawa, Noriko ^a   Higashi, Kenjirou ^b   Nagase, Hiromasa ^a   Endo, Tomohiro ^a   Moribe, Kunikazu ^b   Loftsson, Thorsteinn ^c   Yamamoto, Keiji ^b   Ueda, Haruhisa ^a  

^a HOSHI UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c UNIVERSITY OF ICELAND   (Iceland)

Author keywords

Crystallization; Cyclodextrins; FTIR; Inclusion compounds; Interaction; Milling; Physicochemical properties; Solid state NMR; Thermal analysis; X ray powder diffractometry

Indexed keywords

BETA CYCLODEXTRIN; FENTANYL;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DIFFERENTIAL SCANNING CALORIMETRY; GRINDING; HUMIDITY; HYDROGEN BOND; INFRARED SPECTROSCOPY; PHYSICAL CHEMISTRY; SOLID STATE; X RAY DIFFRACTION;

EID: 78049489785     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22193     Document Type: Article

References (45)

1. Paix A, Coleman A, Lees J, Grigson J, Brooksbank M, Thorne D, Ashby M. 1995. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain 63: 263-269.
2. Mercadante S. 1999. Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer 86: 1856-1866.
3. Labroo RB, Paine MF, Thummel KE, Kharasch ED. 1997. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: Implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 25: 1072-1080.
4. Prodduturi S, Smith GJ, Wokovich AM, Doub WH, Westenberger BJ, Buhse L. 2009. Reservoir based fentanyl transdermal drug delivery systems: Effect of patch age on drug release and skin permeation. Pharm Res 26: 1344-1352.
5. Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA, Frigerio V, Ingham J, Loseth DB, Nordbrock E, Rhiner M. 1999. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: A controlled dose titration study. Pain 79: 303-312.
6. Streisand JB, Busch MA, Egan TD, Smith BG, Gay M, Pace NL. 1998. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 88: 310-316.
7. Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. 1998. Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 90: 611-616.
8. Uekama K, Hirayama F, Irie T. 1998. Cyclodextrin drug carrier systems. Chem Rev 98: 2045-2076.
9. Szente L, Szejtli J. 1999. Highly soluble cyclodextrin derivatives: Chemistry, properties, and trends in development. Adv Drug Deliv Rev 36: 17-28.
10. Hedges AR. 1998. Industrial applications of cyclodextrins. Chem Rev 98: 2035-2044.
11. Braga D, Grepioni F. 2004. Reactions between or within molecular crystals. Angew Chem Int Ed Engl 43: 4002-4011.
12. Holvoet C, Plaizier-Vercammen J, Vander Heyden Y, Gabriëls M, Camu F. 2003. Preparation and in-vitro release rate of fentanyl-cyclodextrin complexes for prolonged action in epidural analgesia. Int J Pharm 265: 13-26.
13. Szejtli J. 1996. Chemistry, physical and biological properties of cyclodextrins. In: Szejtli J, Osa T, volume editors. Comprehensive supramolecular chemistry, vol. 3, Cyclodextrins, Oxford: Pergamon. pp. 5-40.
14. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Montgomery JA Jr., Vreven T, Kudin KN, Burant JC, Millam JM, Iyengar SS, Tomasi J, Barone V, Mennucci B, Cossi M, Scalmani G, Rega N, Petersson GA, Nakatsuji H, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Klene M, Li X, Knox JE, Hratchian HP, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Ayala PY, Morokuma K, Voth GA, Salvador P, Dannenberg JJ, Zakrzewski VG, Dapprich S, Daniels AD, Strain MC, Farkas O, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Ortiz JV, Cui Q, Baboul AG, Clifford S, Cioslowski J, Stefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Martin RL, Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayakkara A, Challacombe M, Gill PMW, Johnson B, Chen W, Wong MW, Gonzalez C, Pople J. 2004. Gaussian 03, revision D.01. Wallingford, CT: Gaussian, Inc.
15. Ogawa N, Nagase H, Endo T, Loftsson T, Ueda H. 2009. Crystal struture of fentanyl base. Anal Sci X-Ray Struc Anal Online 25: 83-84.
16. Macrae CF, Bruno IJ, Chisholm JA, Edgington PR, McCabe P, Pidcock E, Rodriguez-Monge L, Taylor R, Van de Streek J, Wood PA. 2008. Mercury CSD 2.0-New features for the visualization and investigation of crystal structures. J Appl Cryst 41: 466-470.
17. Macrae CF, Edgington PR, McCabe P, Pidcock E, Shields GP, Taylor R, Towler M, Van de Streek J. 2006. Mercury: Visualization and analysis of crystal structures. J Appl Cryst 39: 453-457.
18. Bruno IJ, Cole JC, Edgington PR, Kessler MK, Macrae CF, McCabe P, Pearson J, Taylor R. 2002. New software for searching the Cambridge Structural Database and visualising crystal structures. Acta Cryst B58: 389-397.
19. Taylor R, Macrae CF. 2001. Rules governing the crystal packing of mono- and di-alcohols. Acta Cryst B57: 815-827.
20. Allen FH. 2002. The Cambridge Structural Database: A quarter of a million crystal structures and rising. Acta Cryst B58: 380-388.
21. Roy SD, Flynn GL. 1988. Solubility and related physicochemical properties of narcotic analgesics. Pharm Res 5: 580-586.
22. Guitton J, Désage M, Alamercery S, Dutruch L, Dautraix S, Perdrix JP, Brazier JL. 1997. Gas chromatographic-mass spectrometry and gas chromatographic Fourier transform infrared spectroscopy assay for the simultaneous identification of fentanyl metabolites. J Chromatogr B Biomed Appl 693: 59-70.
23. Nakai Y, Yamamoto K, Terada K, Akimoto K. 1984. The dispersed states of medicinal molecules in ground mixtures with α-or β-cyclodextrin. Chem Pharm Bull 32: 685-691.
24. Moribe K, Yonemochi E, Oguchi T, Nakai Y, Yamamoto K. 1995. Peculiar peak shifts in the IR spectrum of benzoic acid crystals by compression with methylated additives. Chem Pharm Bull 43: 666-670.
25. Ayala-Zavala JF, Soto-Valdez H, González-León A, Álvarez-Parrilla E, Martín-Belloso O, González-Aguilar GA. 2008. Microencapsulation of cinnamon leaf (Cinnamomum zeylanicum) and garlic (Allium sativum) oils in β-cyclodextrin. J Incl Phenom Macrocycl Chem 60: 359-368.
26. Fernandes CM, Vieira MT, Veiga FJB. 2002. Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur J Pharm Sci 15: 79-88.
27. Hayashi S, Oobatake M, Nakamura R, Machida K. 1991. Interpretation for the anomaly of the C=O stretching band in benzoic acid crystal. J Chem Phys 94: 4446-4452.
28. Nagaoka S, Terao T, Imashiro F, Saika A, Hirota N, Hayashi S. 1983. An NMR relaxation study on the proton transfer in the hydrogen bonded carboxylic acid dimers. J Chem Phys 79: 4694-4703.
29. 13C chemical shifts. J Am Chem Soc 110: 3820-3829.
30. 13C-CP/MAS NMR studies of the cyclomalto-oligosaccharide (cyclodextrin) hydrates. Carbohydr Res 233: 1-14.
31. Cunha-Silva L, Teixeira-Dias JJC. 2004. How humidity affects the solid-state inclusion of 2-phenoxyethanol in β-cyclodextrin: A comparison with β-cyclodextrin. New J Chem 28: 200-206.
32. 13C-NMR spectroscopy, X-ray crystallography, and theoretical calculations. Chem Pharm Bull 51: 929-934.
33. Mollica G, Geppi M, Pignatello R, Veracini CA. 2006. Molecular properties of flurbiprofen and its solid dispersions with Eudragit RL100 studied by high- and low-resolution solid-state nuclear magnetic resonance. Pharm Res 23: 2129-2140.
34. Nishiwaki A, Watanabe A, Higashi K, Tozuka Y, Moribe K, Yamamoto K. 2009. Molecular states of prednisolone dispersed in folded sheet mesoporous silica (FSM-16). Int J Pharm 378: 17-22.
35. Kuo SW, Chang FC. 2001. Studies of miscibility behavior and hydrogen bonding in blends of poly(vinylphenol) and poly(vinylpyrrolidone). Macromolecules 34: 5224-5228.
36. 15N-a mobile NMR sensor for surface acidity and surface defects of mesoporous silica. J Phys Chem B 107: 11924-11939.
37. Nakai Y, Yamamoto K, Terada K, Kajiyama A, Sasaki I. 1986. Properties of crystal water of α-, β-, and γ-cyclodextrin. Chem Pharm Bull 34: 2178-2182.
38. Nakai Y, Yamamoto K, Terada K, Sasaki I. 1986. Crystallization of amorphous α-, β-, γ- cyclodextrin by water sorption. Yakugaku Zasshi 106: 420-424.
39. Kawano K, Nakai Y. 1985. Crystallization of the ground mixtures of α-, β-cyclodextrins by water vapor adsorption. Yakugaku Zasshi 105: 1071-1077.
40. Caira MR. 2001. On the isostructurality of cyclodextrin inclusion complexes and its practical utility. Revue Roumaine de Chimie 46: 371-386.
41. Pereira CCL, Nolasco M, Braga SS, Almeida Paz FA, Ribeiro-Claro P, Pillinger M, Gonςalves IS. 2007. A combined theoretical-experimental study of the inclusion of niobocene dichloride in native and permethylated β-cyclodextrins. Organometallics 26: 4220-4228.
42. Mentzafos D, Mavridis IM, Le Bas G, Tsoucaris G. 1991. Structure of the 4-tert-butylbenzyl alcohol-β-cyclodextrin complex. Common features in the geometry of β-cyclodextrin dimeric complexes. Acta Cryst B47: 746-757.
43. Wang EJ, Yan Z, Cai J. 2007. Crystal structure of a cyclomaltoheptaose-4-Hydroxybiphenyl inclusion complex. Carbohydr Res 342: 1530-1534.
44. Makedonopoulou S, Papaioannou J, Argyroglou I, Mavridis IM. 2000. Crystal structures of the inclusion complexes of β-cyclodextrin with aliphatic monoacids tridecanoic acid and (Z)-tetradec-7-enoic acid. Formation of [3]pseudorotaxanes. J Incl Phenom Macrocycl Chem 36: 191-215.
45. Makedonopoulou S, Mavridis IM, Yannakopoulou K, Papaioannou J. 1998. Organisation of long aliphatic monocarboxylic acids in β-cyclodextrin channels: Crystal structures of the inclusion complexes of tridecanoic acid and (Z)-tetradec-7-enoic acid in β-cyclodextrin. Chem Commun 19: 2133-2134.